Clinician author Kevin Chang, PharmD, writes about PACAP as a distinct, druggable migraine pathway independent of CGRP, offering a promising option for patients who don't respond to current therapies.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jessica Ailani, MD. [LISTEN TIME: 17 minutes]

The intravenous (IV) part of the phase IIb dose-finding PROCEED trial of bocunebart (Lu AG09222) met its primary endpoint in migraine prevention, demonstrating a statistically significant difference t...

Denmark's Lundbeck said on Thursday its experimental drug bocunebart cut monthly migraine days in a mid-stage study, ​supporting further development of a new type of ‌treatment for migraine, one of th...

· The intravenous (IV) part of the phase IIb dose-finding PROCEED trial of bocunebart (Lu AG09222)

Lundbeck will present new migraine data at the European Academy of Neurology Congress 2026, taking place from 27–30 June in Geneva.

Lundbeck seems to have brought its migraine prevention drug bocunebart back on track with positive data for an intravenous formulation.

Slate Medicines emerges with $130M Series A and DartsBio's migraine drug SLTE-1009, competing with Lundbeck's bocunebart in PACAP inhibitor space. Led by Gregory Oakes.

Bocunebart shows significant reduction in monthly migraine days in patients with previous treatment failures

Lundbeck presents significant new findings for eptinezumab and bocunebart at EAN 2026, focusing on patient outcomes and innovation in migraine prevention.

Lundbeck has announced positive Phase IIb trial results for bocunebart, showcasing its potential in preventing migraines for patients with previous treatment failures.

At the AHS Congress 2026, Lundbeck unveiled positive Phase IIb results for bocunebart, indicating potential in migraine prevention for treatment-resistant patients.

Lundbeck will present groundbreaking new data on migraine, childhood epilepsy, and MSA at AAN 2026, showcasing its commitment to advanced treatments.

Five migraine presentations will showcase Lundbeck's current and future approaches to migraine prevention, including new data for eptinezumab and Phase IIb PROCEED primary data for the investigational treatment, bocunebart Eptinezumab data explore patient-centered outcomes in chronic...

Seven abstracts represent data across migraine, childhood-onset epilepsy and multiple system atrophy (MSA), highlighting Lundbeck's biology-driven approach to developing treatments for serious brain diseases Oral presentation of new Phase 1 safety and tolerability data for bocunebart (Lu...

Seven abstracts represent data across migraine, childhood-onset epilepsy and multiple system atrophy (MSA), highlighting Lundbeck's biology-driven approach to developing treatments for serious brain diseases Oral presentation of new Phase 1 safety and tolerability data for bocunebart (Lu...

This biweekly Neuroscience video recap highlights regulatory approvals, positive clinical data, and new neurology program launches shaping patient care and market access. 🔬 Key Highlights This Episode: 🟢 Vyepti approved in South Korea 🟢 Otsuka neurology program 🟢 Ozanimod preserves MS cognition 🟢 Bocunebart Phase IIb positive data 🟢 Aquipta receives European approval 🟢 AQNEURSA EMA variation submission 🟢 NGN-401 EMBOLDEN dosing complete 🟢 ACTIVATE Phase 2b topline in GBA Parkinson’s Chapters: 0:00 Introduction 0:08 Vyepti approved in South Korea 0:22 Otsuka neurology program 0:35 Ozanimod preserves MS cognition 0:49 Bocunebart Phase IIb positive data 1:03 Aquipta receives European approval 1:18 AQNEURSA EMA variation submission 1:31 NGN-401 EMBOLDEN dosing complete 1:46 ACTIVATE Phase 2b topline in GBA Parkinson’s 2:02 How to reach us 📢 Stay Ahead in Neuroscience Research! ✅ Like, share, and subscribe for future updates on Neuroscience ✅ Visit www.lqventures.com for expert healthcare insights and consulting services. ✅ Contact LucidQuest at info@lqventures.com for strategic guidance on Neuroscience innovations and clinical research. 🔔 Turn on notifications so you never miss an update! #Neuroscience #FDA #EMA #Migraine #MultipleSclerosis #RareDisease #ClinicalTrials #PharmaNews #LucidQuest

AstraZeneca’s Saphnelo subcutaneous formulation faces a setback with the FDA's complete response letter, though resubmission is planned. Lundbeck’s bocunebart shows promise in reducing migraine days. Roche’s fenebrutinib demonstrates a 12% reduction in disability progression in PPMS. Bone-Viva shows potential for improving bone density in women with osteoporosis. Kisqali® gets a positive recommendation for high-risk breast cancer patients in Canada. Merck’s KEYTRUDA® receives approval for platinum-resistant ovarian cancer, while a menstrual blood test shows promise for cervical cancer screening.

Lundbeck said its next-generation migraine prevention drug cleared the bar in a Phase 2b study, setting the company up for late-stage trials that could start this year. The Danish drugmaker said the IV-delivered medicine, bocunebart ...